復星醫藥(600196.SH):控股子公司復宏漢霖與FBD簽訂《許可協議》
格隆匯6月30日丨復星醫藥(600196.SH)公佈,公司控股子公司復宏漢霖與FBD簽訂《許可協議》,根據約定,雙方將就FBD在研的(1)HCB101(即SIRPα-Fc融合蛋白)、及(2)任何含有該分子作為其活性成分的藥物於約定許可區域和領域內(即用於人類疾病治療,下同)的開發、生產及商業化開展合作。
HCB101(即“許可分子”)是FBD在研的一種SIRPα-Fc融合蛋白,由人信號調節蛋白α(SIRPα)的工程化IgV結構域與IgG4Fc融合而成。HCB101能夠以高親和力與CD47結合,抑制野生型SIRPα的結合,並增強巨噬細胞對腫瘤細胞的吞噬作用。以該分子研發的HCB101注射液在早期臨牀試驗中已展現出對腫瘤患者(包括實體瘤)的初步療效。其中,截至本公吿日期,HCB101注射液於中國境內處於Ib/IIa期臨牀試驗中。截至本公吿日期,全球範圍內尚無同靶點藥物獲批上市。
根據約定,復宏漢霖將就本次合作向FBD支付至多5,900萬美元(包括首付款、開發及監管里程碑付款)。基於許可產品於區域1的年度淨銷售額(定義依約定)達成情況,復宏漢霖應依約向FBD支付至多14,300萬美元的商業里程碑款項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.